Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
about
Resveratrol for treatment of type 2 diabetes mellitusEarly Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsConcepts and clinical use of ultra-long basal insulinPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingDe novo glomerular diseases after renal transplantationAutonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study.Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.The Role of Systemic Risk Factors in Diabetic RetinopathyRationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Pharmacology in peripheral arterial disease: what the interventional radiologist needs to know.The Effect of Cigarette Smoking on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis.The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney DiseaseCluster Randomised Trials in Cochrane Reviews: Evaluation of Methodological and Reporting PracticeHuangqi Guizhi Wuwu Decoction for treating diabetic peripheral neuropathy: a meta-analysis of 16 randomized controlled trials.The Prevention and Treatment of Retinal Complications in Diabetes.Glucose and fatty acid metabolism in infarcted heart from streptozotocin-induced diabetic rats after 2 weeks of tissue remodeling.An assessment of randomized controlled trials (RCTs) for non-communicable diseases (NCDs): more and higher quality research is required in less developed countries.Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain)The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusEffects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.Situational analysis of services for diabetes and diabetic retinopathy and evaluation of programs for the detection and treatment of diabetic retinopathy in India: Methods for the India 11-city 9-state studyReported Benefits of Insulin Therapy for Better Glycemic Control in Type 2 Diabetic Patients-Is This Applicable in Saudi Patients?Associations between metabolic dysregulation and circulating biomarkers of fibrosis: the Cardiovascular Health Study.Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.Congenital Heart Disease With and Without Cyanotic Potential and the Long-term Risk of Diabetes Mellitus: A Population-Based Follow-up StudyIntensive Glycemic Control in Type 2 Diabetes Mellitus -- A Balancing Act of Latent Benefit and Avoidable Harm: A Teachable Moment.Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis.Effects of glucose-lowering agents on ischemic stroke.Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy.Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.Skepticism is unjustified.Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.Metabolic control and hypoglycaemia in people with type 2 diabetes on conventional or intensified insulin therapy: a 22 year retrospective single centre survey.Update on management of diabetic foot ulcers.Quaternary prevention: reviewing the concept.The Role of Glycemic Control and Variability in Diabetic Retinopathy.Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain.
P2860
Q24188321-3C95470C-891E-4E23-8EB7-F1F8D6D8DE18Q26767164-D8407502-592C-40C4-9171-4AF4F677AF8AQ26770354-6AF6DF54-982C-4858-A562-DD870459665CQ26774021-1BFF0648-E5D6-4DE7-A555-8811B19281FEQ26992979-85220E9B-A243-408A-AD67-DBE2C2ED6FDDQ27005877-88AA9D1D-41A4-414E-9334-FC79D3B60585Q30361557-EF4363AA-C6B0-44BD-B564-5EFD0CF30564Q31107244-8960503C-4963-4F21-A338-BB7720F1A331Q33556240-8719F3B3-96F3-4F20-868D-51B57F3F071BQ33689773-38D736BA-F335-4222-8BB5-1E3FA0E825BBQ33812170-CE81B398-320A-49AF-BEA3-2C9740ABE201Q34513880-D5BE9FFA-B8F9-4182-9304-5BB096B6D16EQ35876600-55B85BDB-3AFF-436A-A324-C4CB9301BE9FQ35914820-8B51B5C1-8F2C-4EDB-A3A8-5058AA275E20Q35959642-9585D88A-2405-4A13-AA65-E906EFE8642CQ36139159-405853F6-1C84-4643-83CB-B140E89676D2Q36245823-97FC0700-D449-4251-9FE0-9F2CEC6727D3Q36267548-D932C09A-DEFE-4E23-809F-68F90C54B6D7Q36273547-D332986B-AF1C-4D25-B18D-C594A4E238D8Q36374753-488EB438-A374-4150-B157-373C11B294CAQ36592820-C689944A-CEE7-47F9-A94E-B8CC7F5AB120Q36633079-16D4D174-D0A4-466A-87C5-428AE45375A4Q36842799-259F18C5-4A41-420A-B944-6DADE90E42F4Q36989048-FE518AC4-4344-4249-B478-A4F5651A4599Q37082373-DBBCA673-2EDC-4D7D-9B0A-AB1967EB4050Q37154927-5B4A0131-C3FE-426E-B2ED-D2436D7D7AC7Q37240615-7BDA39C3-F71A-4901-894A-69C3C8630BA3Q37310949-6859AD90-095C-4B9D-B5C9-1BA8899D6E9DQ37390839-72010CCD-72F3-4B5E-BDFD-6B1A523A4164Q38364968-D80C43C5-60F1-485E-BBD8-DABA184A75BDQ39427199-0312A329-FCC5-4E0C-BBB1-B3A0844C1BD8Q40403410-B15DC9AC-03E5-48A7-B05E-465C5C7930ACQ41145183-513912E3-159F-4464-857F-F40136A24410Q42733938-678AB5ED-E217-422C-BD73-86B19D0ECA43Q47443616-C7D55592-3758-49BB-959C-953FA8973C94Q47909900-F4CF3B37-59D2-4B9E-A9F9-32DAC44E9780Q48043438-461CF8F8-4547-44E7-AB63-1C87E2AC94D2Q48135085-82FB1F33-595C-4470-960C-27FCFD290C14Q48211404-BCF30558-6056-43EB-AF83-93A2EE9618AFQ49225560-F0DF56D1-9A87-4A24-860B-BB7EC6FECF90
P2860
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@ast
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en-gb
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@nl
type
label
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@ast
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en-gb
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@nl
prefLabel
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@ast
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en-gb
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@nl
P2093
P2860
P3181
P1476
Targeting intensive glycaemic ...... l for type 2 diabetes mellitus
@en
P2093
Allan Vaag
Bianca Hemmingsen
Søren S Lund
Thomas P Almdal
P2860
P3181
P356
10.1002/14651858.CD008143.PUB3
P577
2013-11-11T00:00:00Z